| Primary |
| Product Used For Unknown Indication |
62.7% |
| Bronchitis |
6.8% |
| Pneumonia |
5.9% |
| Respiratory Tract Infection |
5.1% |
| Allergy Test |
2.5% |
| Drug Use For Unknown Indication |
1.7% |
| Laryngitis |
1.7% |
| Oropharyngeal Pain |
1.7% |
| Otitis Media Acute |
1.7% |
| Prophylaxis |
1.7% |
| Acute Tonsillitis |
0.8% |
| Angina Pectoris |
0.8% |
| Antibiotic Prophylaxis |
0.8% |
| Cystitis |
0.8% |
| Dental Care |
0.8% |
| Dyspnoea |
0.8% |
| Dysuria |
0.8% |
| Ear Infection |
0.8% |
| Feeling Cold |
0.8% |
| Hyperuricaemia |
0.8% |
|
| Urticaria |
14.0% |
| Rash |
12.0% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
10.0% |
| Pruritus |
10.0% |
| Acute Generalised Exanthematous Pustulosis |
8.0% |
| Dermatitis Exfoliative |
4.0% |
| Face Oedema |
4.0% |
| Palatal Oedema |
4.0% |
| Pharyngeal Oedema |
4.0% |
| Rash Pustular |
4.0% |
| Stevens-johnson Syndrome |
4.0% |
| Syncope |
4.0% |
| Toxic Epidermal Necrolysis |
4.0% |
| Anaphylactic Reaction |
2.0% |
| Anaphylactic Shock |
2.0% |
| Coagulation Factor Viii Level Decreased |
2.0% |
| Diarrhoea |
2.0% |
| Drug Eruption |
2.0% |
| Eosinophilia |
2.0% |
| Hepatic Function Abnormal |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
37.3% |
| Pneumonia |
6.5% |
| Pulmonary Embolism |
5.9% |
| Pulmonary Tuberculosis |
5.9% |
| Allergy Test |
5.3% |
| Disseminated Tuberculosis |
4.7% |
| Lung Disorder |
4.7% |
| Drug Use For Unknown Indication |
4.1% |
| Hiv Infection |
4.1% |
| Ear Infection |
3.6% |
| Antiretroviral Therapy |
2.4% |
| Anxiety |
2.4% |
| Ovarian Neoplasm |
2.4% |
| Prophylaxis |
2.4% |
| Appendicitis Perforated |
1.8% |
| Upper Respiratory Tract Infection |
1.8% |
| Acute Tonsillitis |
1.2% |
| Bacterial Infection |
1.2% |
| Cystitis |
1.2% |
| Depression |
1.2% |
|
| Hepatitis |
15.2% |
| Dermatitis Exfoliative |
9.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
9.1% |
| Agranulocytosis |
6.1% |
| Neuropathy Peripheral |
6.1% |
| Pollakiuria |
6.1% |
| Pyrexia |
6.1% |
| Transaminases Increased |
6.1% |
| Cardiac Failure |
3.0% |
| Dysentery |
3.0% |
| Generalised Erythema |
3.0% |
| Hepatocellular Injury |
3.0% |
| Kounis Syndrome |
3.0% |
| Nausea |
3.0% |
| Pain |
3.0% |
| Pancreatitis |
3.0% |
| Pleural Effusion |
3.0% |
| Pruritus |
3.0% |
| Rash Pustular |
3.0% |
| Regurgitation |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
46.4% |
| Drug Use For Unknown Indication |
5.0% |
| Diabetes Mellitus |
3.9% |
| Multiple Sclerosis |
3.9% |
| Type 2 Diabetes Mellitus |
3.9% |
| Antifungal Prophylaxis |
3.4% |
| Mucosal Inflammation |
3.4% |
| Prophylaxis Of Nausea And Vomiting |
3.4% |
| Squamous Cell Carcinoma |
3.4% |
| Dyspnoea |
2.8% |
| Prophylaxis |
2.8% |
| Pulmonary Tuberculosis |
2.8% |
| Atrial Fibrillation |
2.2% |
| Bipolar Disorder |
2.2% |
| Urinary Tract Infection |
2.2% |
| Anaemia |
1.7% |
| Breast Cancer Metastatic |
1.7% |
| Bronchitis |
1.7% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Crohn's Disease |
1.7% |
|
| Tubulointerstitial Nephritis |
18.2% |
| Renal Failure |
9.1% |
| Renal Failure Acute |
9.1% |
| Urinary Tract Infection |
9.1% |
| International Normalised Ratio Increased |
6.1% |
| Vomiting |
6.1% |
| Atrial Fibrillation |
3.0% |
| Bicytopenia |
3.0% |
| Cholelithiasis |
3.0% |
| Hyperaesthesia |
3.0% |
| Hyporeflexia |
3.0% |
| Ileus Paralytic |
3.0% |
| Immune Thrombocytopenic Purpura |
3.0% |
| Liver Injury |
3.0% |
| Loss Of Consciousness |
3.0% |
| Malnutrition |
3.0% |
| Memory Impairment |
3.0% |
| Muscle Haemorrhage |
3.0% |
| No Therapeutic Response |
3.0% |
| Obstructive Airways Disorder |
3.0% |
|
| Interacting |
| Ulcer |
27.3% |
| Atrial Fibrillation |
18.2% |
| Peritonsillar Abscess |
18.2% |
| Deep Vein Thrombosis |
9.1% |
| Pulmonary Embolism |
9.1% |
| Thrombosis |
9.1% |
| Upper Respiratory Tract Infection |
9.1% |
|
| Myocardial Infarction |
33.3% |
| Odynophagia |
33.3% |
| Skin Necrosis |
33.3% |
|
